Comparison of bioluminescent kinase assays using substrate depletion and product formation

Assay and Drug Development Technologies

Volumn 7, Issue 6, 2009, Pages 606-614

  Tanega, Cordelle ^a   Shen, Min ^a   Mott, Bryan T ^a   Thomas, Craig J ^a   MacArthur, Ryan ^a   Inglese, James ^a   Auld, Douglas S ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATASE; ADENOSINE TRIPHOSPHATE; LUCIFERASE; PHENYLPYRIMIDINE DERIVATIVE; PHOSPHOTRANSFERASE; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN CLK4; PROTEIN CLK4 INHIBITOR; PROTEIN KINASE; PROTEIN KINASE C; PTERIDINONE; QUINAZOLINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; BIOLUMINESCENCE; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME ASSAY; ENZYME SUBSTRATE; HIGH THROUGHPUT SCREENING; MICROTITER PLATE ASSAY; QUANTITATIVE ANALYSIS; REPRODUCIBILITY; STRUCTURE ACTIVITY RELATION;

ADENOSINE DIPHOSPHATE; CHEMISTRY TECHNIQUES, ANALYTICAL; LUMINESCENT MEASUREMENTS; LUMINESCENT PROTEINS; PROTEIN INTERACTION MAPPING; PROTEIN-SERINE-THREONINE KINASES; PROTEIN-TYROSINE KINASES; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY;

EID: 76449108493     PISSN: 1540658X     EISSN: None     Source Type: Journal    
DOI: 10.1089/adt.2009.0230     Document Type: Article

References (37)

1. Segel HI. Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady State Enzyme Systems. John Wiley and Sons, New York, 1975.
2. Eglen RM, Reisine T. The current status of drug discovery against the human kinome. Assay Drug Dev Technol 2009;7:22-43.
3. Beasley JR, Dunn DA, Walker TL, Parlato SM, Lehrach JM, Auld DS: Evaluation of compound interference in immobilized metal ion affinity-based fluorescence polarization detection with a four million member compound collection. Assay Drug Dev Technol 2003;1:455-459.
4. Gaudet EA, Huang KS, Zhang Y, Huang W, Mark D, Sportsman JR: A homogeneous fluorescence polarization assay adaptable for a range of protein serine/ threonine and tyrosine kinases. J Biomol Screen 2003;8:164-175.
5. Loomans EE, van Doornmalen AM, Wat JW, Zaman GJ: High-throughput screening with immobilized metal ion affinity-based fluorescence polarization detection, a homogeneous assay for protein kinases. Assay Drug Dev Technol 2003;1:445-453.
6. Sportsman JR, Gaudet EA, Boge A: Immobilized metal ion affinity-based fluorescence polarization (IMAP): advances in kinase screening. Assay Drug Dev Technol 2004;2:205-214.
7. Turek-Etienne TC, Kober TP, Stafford JM, Bryant RW: Development of a fluorescence polarization AKT serine/threonine kinase assay using an immobilized metal ion affinity-based technology. Assay Drug Dev Technol 2003;1:545-553.
8. Rodems SM, Hamman BD, Lin C, Zhao J, Shah S, Heidary D, et al.: A FRET-based assay platform for ultra-high density drug screening of protein kinases and phosphatases. Assay Drug Dev Technol 2002;1:9-19.
9. Glickman JF, Schmid A, Ferrand S: Scintillation proximity assays in highthroughput screening. Assay Drug Dev Technol 2008;6:433-455.
10. Charter NW, Kauffman L, Singh R, Eglen RM: A generic, homogenous method for measuring kinase and inhibitor activity via adenosine 5?-diphosphate accumulation. J Biomol Screen 2006;11:390-399.
11. Huss KL, Blonigen PE, Campbell RM: Development of a Transcreener kinase assay for protein kinase A and demonstration of concordance of data with a filter-binding assay format. J Biomol Screen 2007;12:578-584.
12. Kleman-Leyer KM, Klink TA, Kopp AL, Westermeyer TA, Koeff MD, Larson BR, et al.: Characterization and optimization of a red-shifted fluorescence polarization ADP detection assay. Assay Drug Dev Technol 2009;7:56-67.
13. Fan F, Wood KV: Bioluminescent assays for high-throughput screening. Assay Drug Dev Technol 2007;5:127-136.
14. Schroter T, Minond D, Weiser A, Dao C, Habel J, Spicer T, et al.: Comparison of miniaturized time-resolved fluorescence resonance energy transfer and enzyme-coupled luciferase high-throughput screening assays to discover inhibitors of Rho-kinase II (ROCK-II). J Biomol Screen 2008;13:17-28.
15. Singh P, Harden BJ, Lillywhite BJ, Broad PM: Identification of kinase inhibitors by an ATP depletion method. Assay Drug Dev Technol 2004;2:161-169.
16. Wu G, Yuan Y, Hodge CN: Determining appropriate substrate conversion for enzymatic assays in high-throughput screening. J Biomol Screen 2003;8:694-700.
17. Inglese J, Johnson RL, Simeonov A, Xia M, Zheng W, Austin CP, et al.: Highthroughput screening assays for the Identification of chemical probes. Nat Chem Biol 2007;3:466-479.
18. Auld DS, Zhang YQ, Southall NT, Rai G, Landsman M, Maclure J, et al.: A basis for reduced chemical library inhibition of firefl y luciferase obtained from directed evolution. J Med Chem 2009;52:1450-1458.
19. Muraki M, Ohkawara B, Hosoya T, Onogi H, Koizumi J, Koizumi T, et al.: Manipulation of alternative splicing by a newly developed inhibitor of Clks. J Biol Chem 2004;279:24246-24254.
20. Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, Yasgar A, et al.: Quantitative high-throughput screening: a titration-based approach that effi-ciently identifi es biological activities in large chemical libraries. Proc Natl Acad Sci USA 2006;103:11473-11478.
21. Yasgar A, Shinn P, Jadhav A, Auld, DS, Michael S, Zheng W, et al.: Compound management for quantitative high-throughput screening. J Assoc Lab Automation 2008;13:79-89.
22. Niles WD, Coassin PJ: Piezo-and solenoid valve-based liquid dispensing for miniaturized assays. Assay Drug Dev Technol 2005;3:189-202.
23. Cleveland PH, Koutz PJ: Nanoliter dispensing for uHTS using pin tools. Assay Drug Dev Technol 2005;3:213-225.
24. Shukla SJ, Nguyen DT, Macarthur R, Simeonov A, Frazee WJ, Hallis TM, et al.: Identification of pregnane X receptor ligands using time-resolved fluorescence resonance energy transfer and quantitative high-throughput screening. Assay Drug Dev Technol 2009;7:143-169.
25. Eastwood BJ, Farmen MW, Iversen PW, Craft TJ, Smallwood JK, Garbison KE, et al.: The minimum signifi cant ratio: a statistical parameter to characterize the reproducibility of potency estimates from concentration-response assays and estimation by replicate-experiment studies. J Biomol Screen 2006;11:253-261.
26. MacArthur R, Leister W, Veith H, Shinn P, Southall N, Austin CP, et al.: Monitoring compound integrity with cytochrome P450 assays and qHTS. J Biomol Screen 2009;14:538-546.
27. Bolton EE, Wang Y, Thiessen PA, Bryant SH: PubChem: integrated platform of small molecules and biological activities. Annu Rep Comput Chem 2008; 4:217-241.
28. http://pubchem.ncbi.nlm.nih.gov/
29. http://www.promega.com/tbs/tm313/tm313.pdf
30. http://www.promega.com/tbs/tb372/tb372.pdf
31. Chao Q, Deng L, Shih H, Leoni LM, Genini D, Carson DA, et al.: Substituted isoquinolines and quinazolines as potential antiinflammatory agents. Synthesis and biological evaluation of inhibitors of tumor necrosis factor alpha. J Med Chem 1999;42:3860-3873.
32. Fry DW, Kraker AJ, McMichael A, Ambroso LA, Nelson JM, Leopold WR, et al.: A specific inhibitor of the epidermal growth factor receptor tyrosine kinase. Science 1994;265:1093-1095.
33. http://www.ncbi.nlm.nih.gov/sites/entrez?db=pcsubstance&term=PCOP
34. Mott BT, Tanega C, Shen M, Maloney DJ, Shinn P, Leister W, et al.: Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk). Bioorg Med Chem Lett 2009;19:6700-6705.
35. Auld DS, Southall NT, Jadhav A, Johnson RL, Diller DJ, Simeonov A, et al.: Characterization of chemical libraries for luciferase inhibitory activity. J Med Chem 2008;51:2372-2386.
36. Ching TM: A sensitive and simple assay of starch synthase activity with pyruvate kinase and luciferase. Anal Biochem 1982;122:139-143.
37. Jenkins WT: The pyruvate kinase-coupled assay for ATPases: a critical analysis. Anal Biochem 1991;194:136-139.